Journal of Global Antimicrobial Resistance
metrics 2024
Exploring the forefront of antimicrobial resistance research.
Introduction
The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Infectious Diseases and Clinical Microbiology
Bridging research and clinical practice in infectious health.Infectious Diseases and Clinical Microbiology is a pivotal journal dedicated to advancing our understanding of infectious diseases through rigorous scientific research and clinical practices. Published by DOC DESIGN INFORMATICS CO LTD, this journal serves as a vital platform for researchers, healthcare professionals, and students keen on enhancing their knowledge of microbiological sciences and the clinical implications of infectious agents. With an ISSN of 2667-646X, it aims to disseminate significant findings in the field, enriching the scholarly dialogue surrounding infectious diseases. While currently operating under a traditional access model, the journal encourages global collaboration and knowledge sharing, striving to make a meaningful impact in tackling the challenges posed by infectious diseases. Its content aims to bridge the gap between laboratory research and clinical application, making it an essential resource in the contemporary landscape of global health.
Microbial Drug Resistance
Empowering Research to Combat Drug ResistanceMicrobial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.
CLINICAL MICROBIOLOGY AND INFECTION
Exploring Innovations in MicrobiologyCLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.
International Journal of Antimicrobial Agents
Elevating Research in Microbiology and PharmacologyInternational Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.
Antimicrobial Resistance and Infection Control
Empowering research for a healthier tomorrow.Antimicrobial Resistance and Infection Control is a leading open access journal published by BMC, dedicated to the dissemination of research in the critical area of antimicrobial resistance and its impact on infection control practices. Since its inception in 2012, the journal has quickly established itself as a vital resource for researchers, healthcare professionals, and policymakers, featuring a robust array of studies that address the escalating threats posed by antimicrobial resistance across various contexts. With its impressive Q1 rankings across multiple categories—including Infectious Diseases, Microbiology, Pharmacology, and Public Health—the journal’s influence is underscored by its consistent placement in the upper echelons of academic research. Furthermore, it holds commendable ranks in Scopus, with percentiles placing it in the top tier of its respective fields. The journal serves as an essential platform for innovative research and discussions aimed at curbing the threats of antimicrobial resistance, thereby supporting the global health community in striving for effective solutions to safeguard public health.
Expert Review of Anti-Infective Therapy
Pioneering Reviews in Infectious Disease TherapyExpert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.
Annals of Clinical Microbiology and Antimicrobials
Advancing knowledge in microbiology and antimicrobial research.Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.
Infectious Disease Reports
Transforming knowledge into action against infectious diseases.Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Fostering Breakthroughs in Antimicrobial StrategiesAntimicrobial Agents and Chemotherapy, published by the American Society for Microbiology, is a leading journal in the fields of Infectious Diseases and Pharmacology. With a rich history dating back to its inception in 1963, this esteemed journal provides a vital platform for the dissemination of innovative research and advances in antimicrobials and therapeutic strategies. Currently holding a remarkable Q1 ranking in multiple categories, including Infectious Diseases and Pharmacology (medical), the journal occupies a prestigious position within its discipline, supported by exceptional rankings in Scopus metrics. As an essential resource for researchers, professionals, and students alike, it aims to foster knowledge exchange and inspire new strategies in combating infectious diseases. While not an open-access journal, it remains influential in shaping clinical applications and public health strategies through its rigorous peer-reviewed publications.
Infection and Drug Resistance
Empowering researchers with vital knowledge in pharmacology.Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.